Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.

Xavier Leleu,Maria-Victoria Mateos,Sundar Jagannath,Sosana Delimpasi,Maryana Simonova,Ivan Spicka,Luděk Pour,Iryna Kriachok,Maria Gavriatopoulou,Meletios A. Dimopoulos,Halyna Pylypenko,Holger W. Auner,Benjamin Reuben,Christopher P. Venner,Mamta Garg,Andrew DeCastro,Jatin J. Shah,Sebastian Grosicki,Paul G. Richardson

Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.

2021

Xavier Leleu
Maria-Victoria Mateos
Sundar Jagannath
Sosana Delimpasi
Maryana Simonova
Ivan Spicka
Luděk Pour
Iryna Kriachok
Maria Gavriatopoulou
Meletios A. Dimopoulos
Halyna Pylypenko
Holger W. Auner
Benjamin Reuben
Christopher P. Venner
Mamta Garg
Andrew DeCastro
Jatin J. Shah
Sebastian Grosicki
Paul G. Richardson

8024Background: Lenalidomide (LEN) is typically a frontline therapy for newly diagnosed MM. Patients (pts) with MM refractory to LEN are less likely to repond to other IMiDs and represent a signifi...

Keywords:

in patient
Dexamethasone
Refractory
Oncology
previously treated
Medicine
Internal medicine
Lenalidomide
Multiple myeloma
Bortezomib
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations